Vedana Therapeutics Launches With $46 Million Series A Financing to Advance Next-Generation Migraine Therapies

Source Summary

SEATTLE--(BUSINESS WIRE)--Vedana Therapeutics (“Vedana”), a biotechnology company developing next-generation therapies for migraine prevention, today emerged from stealth with $46 million in Series A financing. The financing was co-led by Westlake BioPartners and Canaan Partners, with participation from Dawn Biopharma and Alexandria Venture Investments. Vedana’s executive team, board, and advisors include leaders who discovered and developed multiple migraine therapies, including approved calci